Cited by 687HER2/EGFR in Cancer ResearchLung Cancer Treatments and MutationsColorectal Cancer Treatments and Studies

The DOI matches its Crossref record; 182 of the 182 references it cites were found in a registry or an index.

Understanding resistance to EGFR inhibitors—impact on future treatment strategies

Open access

Wheeler, Deric L., Dunn, Emily F., Harari, Paul M.·2010·Nature Reviews Clinical Oncology

DOI 10.1038/nrclinonc.2010.97PMC PMC2929287

Open this paper in CoChat — free account

Abstract

EGFR is a tyrosine kinase that participates in the regulation of cellular homeostasis. Following ligand binding, EGFR stimulates downstream cell signaling cascades that influence cell proliferation, apoptosis, migration, survival and complex processes, including angiogenesis and tumorigenesis. EGFR has been strongly implicated in the biology of human epithelial malignancies, with therapeutic applications in cancers of the colon, head and neck, lung, and pancreas. Accordingly, targeting EGFR has been intensely pursued, with the development of a series of promising molecular inhibitors for use in clinical oncology. As is common in cancer therapy, challenges with respect to treatment resistance emerge over time. This situation is certainly true of EGFR inhibitor therapies, where intrinsic and acquired resistance is now well recognized. In this Review, we provide a brief overview regarding the biology of EGFR, preclinical and clinical development of EGFR inhibitors, and molecular mechanisms that underlie the development of treatment resistance. A greater understanding of the mechanisms that lead to EGFR resistance may provide valuable insights to help design new strategies that will enhance the impact of this promising class of inhibitors for the treatment of cancer.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1038/nrclinonc.2010.97

Cites

182 of 182 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to Gefitinib
Lynch, T. J., Bell, D. W., Sordella, R., Gurubhagavatula, S., Okimoto, R. A., Brannigan, B. W., Harris, P. L., Haserlat, S. M., Supko, J. G., Haluska, F. G., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040938 · Cited by 11,486
EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy
Paez, J. G., Jänne, P. A., Lee, J. C., Tracy, S., Greulich, H., Gabriel, S., Herman, P., Kaye, F. J., Lindeman, N., Boggon, T. J., et al. (2004) · Science · doi:10.1126/science.1099314 · Cited by 9,368
Untangling the ErbB signalling network
Yarden, Y., & Sliwkowski, M. X. (2001) · Nature Reviews Molecular Cell Biology · doi:10.1038/35052073 · Cited by 6,974
Erlotinib in Previously Treated Non–Small-Cell Lung Cancer
Shepherd, F. A., Rodrigues Pereira, J., Ciuleanu, T., Tan, E. H., Hirsh, V., Thongprasert, S., Campos, D., Maoleekoonpiroj, S., Smylie, M., Martins, R., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050753 · Cited by 5,419
Radiotherapy plus Cetuximab for Squamous-Cell Carcinoma of the Head and Neck
Bonner, J. A., Harari, P. M., Giralt, J., Azarnia, N., Shin, D. M., Cohen, R. B., Jones, C. U., Sur, R. K., Raben, D., Jassem, J., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa053422 · Cited by 5,109
Self-citation
Cetuximab Monotherapy and Cetuximab plus Irinotecan in Irinotecan-Refractory Metastatic Colorectal Cancer
Cunningham, D., Humblet, Y., Siena, S., Khayat, D., Bleiberg, H., Santoro, A., Bets, D., Mueser, M., Harstrick, A., Verslype, C., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa033025 · Cited by 5,035
MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling
Engelman, J. A., Zejnullahu, K., Mitsudomi, T., Song, Y., Hyland, C., Park, J. O., Lindeman, N., Gale, C.-M., Zhao, X., Christensen, J., et al. (2007) · Science · doi:10.1126/science.1141478 · Cited by 4,496
EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinib
Pao, W., Miller, V., Zakowski, M., Doherty, J., Politi, K., Sarkaria, I., Singh, B., Heelan, R., Rusch, V., Fulton, L., et al. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0405220101 · Cited by 4,338
EGFR Mutation and Resistance of Non–Small-Cell Lung Cancer to Gefitinib
Kobayashi, S., Boggon, T. J., Dayaram, T., Jänne, P. A., Kocher, O., Meyerson, M., Johnson, B. E., Eck, M. J., Tenen, D. G., & Halmos, B. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa044238 · Cited by 3,964
Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer
Van Cutsem, E., Köhne, C.-H., Hitre, E., Zaluski, J., Chang Chien, C.-R., Makhson, A., D'Haens, G., Pintér, T., Lim, R., Bodoky, G., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0805019 · Cited by 3,877
Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group
Moore, M. J., Goldstein, D., Hamm, J., Figer, A., Hecht, J. R., Gallinger, S., Au, H. J., Murawa, P., Walde, D., Wolff, R. A., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.07.9525 · Cited by 3,848
Platinum-Based Chemotherapy plus Cetuximab in Head and Neck Cancer
Vermorken, J. B., Mesia, R., Rivera, F., Remenar, E., Kawecki, A., Rottey, S., Erfan, J., Zabolotnyy, D., Kienzer, H.-R., Cupissol, D., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802656 · Cited by 3,726
K-ras Mutations and Benefit from Cetuximab in Advanced Colorectal Cancer
Karapetis, C. S., Khambata-Ford, S., Jonker, D. J., O'Callaghan, C. J., Tu, D., Tebbutt, N. C., Simes, R. J., Chalchal, H., Shapiro, J. D., Robitaille, S., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0804385 · Cited by 3,622
Acquired Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib Is Associated with a Second Mutation in the EGFR Kinase Domain
Pao, W., Miller, V. A., Politi, K. A., Riely, G. J., Somwar, R., Zakowski, M. F., Kris, M. G., & Varmus, H. (2005) · PLoS Medicine · doi:10.1371/journal.pmed.0020073 · Cited by 3,527
Lapatinib plus Capecitabine for HER2-Positive Advanced Breast Cancer
Geyer, C. E., Forster, J. K., Lindquist, D. L., Chan, S. Y. T., Romieu, C. G., Pieńkowski, T., Jagiełło-Gruszfeld, A., Crown, J. P., Chan, A., Kaufman, B., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa064320 · Cited by 3,458
ERBB receptors and cancer: the complexity of targeted inhibitors
Hynes, N. E., & Lane, H. A. (2005) · Nature reviews. Cancer · doi:10.1038/nrc1609 · Cited by 3,379
Wild-Type KRAS Is Required for Panitumumab Efficacy in Patients With Metastatic Colorectal Cancer
Amado, R. G., Wolf, M., Peeters, M., Van Cutsem, E., Siena, S., Freeman, D. J., Juan, T., Sikorski, R., Suggs, S., Radinsky, R., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.7116 · Cited by 3,207
Multi-Institutional Randomized Phase II Trial of Gefitinib for Previously Treated Patients With Advanced Non–Small-Cell Lung Cancer
Fukuoka, M., Yano, S., Giaccone, G., Tamura, T., Nakagawa, K., Douillard, J., Nishiwaki, Y., Vansteenkiste, J., Kudoh, S., Rischin, D., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.10.038 · Cited by 2,871
Human epidermal growth factor receptor cDNA sequence and aberrant expression of the amplified gene in A431 epidermoid carcinoma cells
Ullrich, A., Coussens, L. M., Hayflick, J. S., Dull, T. J., Gray, A., Tam, A. W., Lee, J., Yarden, Y., Libermann, T. A., Schlessinger, J., et al. (1984) · Nature · doi:10.1038/309418a0 · Cited by 2,751
Efficacy of Gefitinib, an Inhibitor of the Epidermal Growth Factor Receptor Tyrosine Kinase, in Symptomatic Patients With Non–Small Cell Lung Cancer: A Randomized Trial
Kris, M. G., Natale, R. B., Herbst, R. S., Lynch, Jr., Prager, D., Belani, C. P., Schiller, J. H., Kelly, K., Spiridonidis, H., Sandler, A., et al. (2003) · JAMA · doi:10.1001/jama.290.16.2149 · Cited by 2,517
Screening for Epidermal Growth Factor Receptor Mutations in Lung Cancer
Rosell, R., Moran, T., Queralt, C., Porta, R., Cardenal, F., Camps, C., Majem, M., Lopez-Vivanco, G., Isla, D., Provencio, M., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0904554 · Cited by 2,373
Transforming gene product of Rous sarcoma virus phosphorylates tyrosine
Hunter, T. R., & Sefton, B. M. (1980) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.77.3.1311 · Cited by 2,333
KRAS Mutation Status Is Predictive of Response to Cetuximab Therapy in Colorectal Cancer
Lièvre, A., Bachet, J.-B., Le Corre, D., Boige, V., Landi, B., Emile, J.-F., Côté, J.-F., Tomasic, G., Penna, C., Ducreux, M., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-0191 · Cited by 2,229
Isolation of a Mouse Submaxillary Gland Protein Accelerating Incisor Eruption and Eyelid Opening in the New-born Animal
Cohen, S. (1962) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)83739-0 · Cited by 2,202
The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP
Yun, C.-H., Mengwasser, K. E., Toms, A. V., Woo, M. S., Greulich, H., Wong, K.-K., Meyerson, M., & Eck, M. J. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0709662105 · Cited by 2,118
Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer)
Thatcher, N., Chang, A., Parikh, P., Rodrigues Pereira, J., Ciuleanu, T., von Pawel, J., Thongprasert, S., Tan, E. H., Pemberton, K., Archer, V., et al. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67625-8 · Cited by 2,079
Insulin and insulin-like growth factor signalling in neoplasia
Pollak, M. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2536 · Cited by 2,059
Open-Label Phase III Trial of Panitumumab plus Best Supportive Care Compared with Best Supportive Care Alone in Patients with Chemotherapy-Refractory Metastatic Colorectal Cancer
Van Cutsem, E., Peeters, M., Siena, S., Humblet, Y., Hendlisz, A., Neyns, B., Canon, J.-L., Van Laethem, J.-L., Maurel, J., Richardson, G., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.08.1620 · Cited by 1,979
Cetuximab for the Treatment of Colorectal Cancer
Jonker, D. J., O'Callaghan, C. J., Karapetis, C. S., Zalcberg, J. R., Tu, D., Au, H.-J., Berry, S. R., Krahn, M., Price, T., Simes, R. J., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa071834 · Cited by 1,904
Erlotinib in Lung Cancer — Molecular and Clinical Predictors of Outcome
Tsao, M., Sakurada, A., Cutz, J.-C., Zhu, C., Kamel‐Reid, S., Squire, J. A., Lorimer, I. A. J., Zhang, T., Liu, G., Daneshmand, M., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050736 · Cited by 1,815
Gefitinib in Combination With Gemcitabine and Cisplatin in Advanced Non–Small-Cell Lung Cancer: A Phase III Trial—INTACT 1
Giaccone, G., Herbst, R. S., Manegold, C., Scagliotti, G. V., Rosell, R., Miller, V. A., Natale, R. B., Schiller, J. H., von Pawel, J., Pluzanska, A., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.08.001 · Cited by 1,712
Gefitinib in Combination With Paclitaxel and Carboplatin in Advanced Non–Small-Cell Lung Cancer: A Phase III Trial—INTACT 2
Herbst, R. S., Giaccone, G., Schiller, J. H., Natale, R. B., Miller, V. A., Manegold, C., Scagliotti, G. V., Rosell, R., Oliff, I. A., Reeves, J. A., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.07.215 · Cited by 1,701
Fluorouracil, Leucovorin, and Oxaliplatin With and Without Cetuximab in the First-Line Treatment of Metastatic Colorectal Cancer
Bokemeyer, C., Bondarenko, I., Makhson, A. M., Hartmann, J. T., Aparicio, J., de Braud, F., Donea, S., Ludwig, H., Schuch, G., Stroh, C., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.20.8397 · Cited by 1,646
Cetuximab in the treatment of colorectal cancer.
Goldberg, R. M., Venook, A. P., & Schilsky, R. L. (2004) · PubMed · Cited by 1,518
KRAS Mutations and Primary Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib
Pao, W. J., Wang, T. Y., Riely, G. J., Miller, V. A., Pan, Q., Ladanyi, M., Zakowski, M. F., Heelan, R. T., Kris, M. G., & VARMUS, H. E. (2005) · PLoS Medicine · doi:10.1371/journal.pmed.0020017 · Cited by 1,517
Amplification, enhanced expression and possible rearrangement of EGF receptor gene in primary human brain tumours of glial origin
Libermann, T. A., Nusbaum, H. R., Razon, N., Kris, R., Lax, I., Soreq, H., Whittle, N., Waterfield, M. D., Ullrich, A., & Schlessinger, J. (1985) · Nature · doi:10.1038/313144a0 · Cited by 1,503
TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer
Herbst, R. S., Prager, D., Hermann, R., Fehrenbacher, L., Johnson, B. E., Sandler, A., Kris, M. G., Tran, H. T., Klein, P., Li, X., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.02.840 · Cited by 1,490
Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial
Pirker, R., Pereira, J. R., Szczęsna, A., von Pawel, J., Krzakowski, M. J., Ramlau, R., Vynnychenko, I. O., Park, K., Yu, C.-T., Ganul, V., et al. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60569-9 · Cited by 1,346
Mutations of the Epidermal Growth Factor Receptor Gene in Lung Cancer
Kosaka, T., Yatabe, Y., Endoh, H., Kuwano, H., Takahashi, T., & Mitsudomi, T. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-2818 · Cited by 1,220
Novel anticancer targets: revisiting ERBB2 and discovering ERBB3
Baselga, J. M., & Swain, S. M. (2009) · Nature reviews. Cancer · doi:10.1038/nrc2656 · Cited by 1,170
American Society of Clinical Oncology Provisional Clinical Opinion: Testing for KRAS Gene Mutations in Patients With Metastatic Colorectal Carcinoma to Predict Response to Anti–Epidermal Growth Factor Receptor Monoclonal Antibody Therapy
Allegra, C. J., Jessup, J. M., Somerfield, M. R., Hamilton, S. R., Hammond, E. H., Hayes, D. F., McAllister, P. K., Morton, R. F., & Schilsky, R. L. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.21.9170 · Cited by 1,156
Expression of Epiregulin and Amphiregulin and K-ras Mutation Status Predict Disease Control in Metastatic Colorectal Cancer Patients Treated With Cetuximab
Khambata-Ford, S., Garrett, C. R., Meropol, N. J., Basik, M., Harbison, C. T., Wu, S., Wong, T. W., Huang, X., Takimoto, C. H., Godwin, A. K., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.10.5437 · Cited by 1,125
Structural basis for inhibition of the epidermal growth factor receptor by cetuximab
Li, S., Schmitz, K. R., Jeffrey, P. D., Wiltzius, J. J. W., Kussie, P. H., & Ferguson, K. M. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.03.003 · Cited by 1,117
Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry.
Chung, K. Y., Shia, J., Kemeny, N. E., Shah, M., Schwartz, G. K., Tse, A., Hamilton, A., Pan, D., Schrag, D., Schwartz, L., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.08.037 · Cited by 1,081
Epidermal growth factor regulates p21ras through the formation of a complex of receptor, Grb2 adapter protein, and Sos nucleotide exchange factor
Buday, L., & Downward, J. (1993) · Cell · doi:10.1016/0092-8674(93)90146-h · Cited by 1,064
Nuclear localization of EGF receptor and its potential new role as a transcription factor
Lin, S., Makino, K., Xia, W., Matin, A., Wen, Y., Kwong, K. Y., Bourguignon, L., & Hung, M. (2001) · Nature Cell Biology · doi:10.1038/ncb0901-802 · Cited by 1,064
Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib
Kwak, E. L., Sordella, R., Bell, D. W., Godin-Heymann, N., Okimoto, R. A., Brannigan, B. W., Harris, P. L., Driscoll, D. R., Fidias, P. M., Lynch, T. J., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0502860102 · Cited by 966
EPIC: Phase III Trial of Cetuximab Plus Irinotecan After Fluoropyrimidine and Oxaliplatin Failure in Patients With Metastatic Colorectal Cancer
Sobrero, A. F., Maurel, J., Fehrenbacher, L., Scheithauer, W., Abubakr, Y. A., Lutz, M. P., Vega-Villegas, M. E., Eng, C., Steinhauer, E. U., Prausová, J., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.13.1193 · Cited by 955
Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study
Moroni, M., Veronese, S., Benvenuti, S., Marrapese, G., Sartore-Bianchi, A., Di Nicolantonio, F., Gambacorta, M., Siena, S., & Bardelli, A. (2005) · The Lancet Oncology · doi:10.1016/s1470-2045(05)70102-9 · Cited by 941
Phase III Randomized Trial of Cisplatin Plus Placebo Compared With Cisplatin Plus Cetuximab in Metastatic/Recurrent Head and Neck Cancer: An Eastern Cooperative Oncology Group Study
Burtness, B. A., Goldwasser, M. A., Flood, W. A., Mattar, B. I., & Forastiere, A. A. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.02.4646 · Cited by 883
Phase III Study of Erlotinib in Combination With Cisplatin and Gemcitabine in Advanced Non–Small-Cell Lung Cancer: The Tarceva Lung Cancer Investigation Trial
Gatzemeier, U., Pluzanska, A., Szczęsna, A., Kaukel, E., Roubec, J., Rosa, F. D., Milanowski, J., Karnicka-Mlodkowski, H., Pešek, M., Serwatowski, P., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2005.05.1474 · Cited by 875
A randomized phase IIIB trial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer
Hecht, J. R., Mitchell, E., Chidiac, T., Scroggin, C., Hagenstad, C., Spigel, D., Marshall, J., Cohn, A., McCollum, D., Stella, P., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.19.8135 · Cited by 850
KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab
De Roock, W., Piessevaux, H., De Schutter, J., Janssens, M., De Hertogh, G., Personeni, N., Biesmans, B., Van Laethem, J.-L., Peeters, M., Humblet, Y., et al. (2008) · Annals of Oncology · doi:10.1093/annonc/mdm496 · Cited by 827
First-Line Gefitinib in Patients With Advanced Non–Small-Cell Lung Cancer Harboring Somatic EGFR Mutations
Sequist, L. V., Martins, R. G., Spigel, D., Grunberg, S. M., Spira, A., Jänne, P. A., Joshi, V. A., McCollum, D., Evans, T. L., Muzikansky, A., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.8494 · Cited by 820
A Specific Inhibitor of the Epidermal Growth Factor Receptor Tyrosine Kinase
Fry, D. W., Kraker, A. J., McMichael, A., Ambroso, L. A., Nelson, J. M., Leopold, W. R., Connors, R. W., & Bridges, A. J. (1994) · Science · doi:10.1126/science.8066447 · Cited by 806
Clinical definition of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer.
Jackman, D., Pao, W., Riely, G. J., Engelman, J. A., Kris, M. G., Jänne, P. A., Lynch, T., Johnson, B. E., & Miller, V. A. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.24.7049 · Cited by 793
Growth stimulation of A431 cells by epidermal growth factor: identification of high-affinity receptors for epidermal growth factor by an anti-receptor monoclonal antibody.
Kawamoto, T., Sato, J. D., Le, A., Polikoff, J., SATO, G. H., & Mendelsohn, J. M. (1983) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.80.5.1337 · Cited by 791
Biological efficacy of a chimeric antibody to the epidermal growth factor receptor in a human tumor xenograft model.
Goldstein, N. I., Prewett, M. C., Zuklys, K., Rockwell, P., & Mendelsohn, J. M. (1995) · PubMed · Cited by 785
Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by Cetuximab plus chemotherapy
Di Fiore, F., Blanchard, F., Charbonnier, F., Le Pessot, F., Lamy, A., Galais, M. P., Bastit, L., Killian, A., Sesboüé, R., Tuech, J. J., et al. (2007) · British Journal of Cancer · doi:10.1038/sj.bjc.6603685 · Cited by 734
Epidermal growth factor receptor blockade with C225 modulates proliferation, apoptosis, and radiosensitivity in squamous cell carcinomas of the head and neck.
Huang, S., Bock, J. M., & Harari, P. M. (1999) · PubMed · Cited by 719
Self-citation
Insect cell-expressed p180erbB3 possesses an impaired tyrosine kinase activity.
Guy, P. M., Platko, J. V., Cantley, L. C., Cerione, R. A., & Carraway, K. L. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.17.8132 · Cited by 698
c-Src-mediated Phosphorylation of the Epidermal Growth Factor Receptor on Tyr845 and Tyr1101 Is Associated with Modulation of Receptor Function
Biscardi, J. S., Maa, M.-C., Tice, D. A., Cox, M. E., Leu, T.-H., & Parsons, S. J. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.12.8335 · Cited by 649
Inhibition of growth factor production and angiogenesis in human cancer cells by ZD1839 (Iressa), a selective epidermal growth factor receptor tyrosine kinase inhibitor.
Ciardiello, F., Caputo, R., Bianco, R., Damiano, V., Fontanini, G., Cuccato, S., Placido, S. D., Bianco, A. R., & Tortora, G. (2001) · PubMed · Cited by 643
Hepatocyte growth factor induces gefitinib resistance of lung adenocarcinoma with epidermal growth factor receptor-activating mutations
Yano, S., Wang, W., Li, Q., Matsumoto, K., Sakurama, H., Nakamura, T., Ogino, H., Kakiuchi, S., Hanibuchi, M., Nishioka, Y., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-1643 · Cited by 643
The EGFR as a target for anticancer therapy—focus on cetuximab
Baselga, J. M. (2001) · European Journal of Cancer · doi:10.1016/s0959-8049(01)00233-7 · Cited by 585
Nuclear interaction of EGFR and STAT3 in the activation of the iNOS/NO pathway
Lo, H., Hsu, S.-C., Ali‐Seyed, M., Gündüz, M., Xia, W., Wei, Y., Bartholomeusz, G. A., Shih, J. Y., & Hung, M. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.05.007 · Cited by 556
Mechanisms of acquired resistance to cetuximab: role of HER (ErbB) family members
Wheeler, D. L., Huang, S., Kruser, T. J., Nechrebecki, M. M., Armstrong, E. A., Benavente, S., Gondi, V, Hsu, K.-T., & Harari, P. M. (2008) · Oncogene · doi:10.1038/onc.2008.19 · Cited by 550
Self-citation
Epidermal growth factor receptor (HER1) tyrosine kinase inhibitor ZD1839 (Iressa) inhibits HER2/neu (erbB2)-overexpressing breast cancer cells in vitro and in vivo.
Moulder, S. L., Yakes, F. M., Muthuswamy, S. K., Bianco, R., Simpson, J. F., & Arteaga, C. L. (2001) · PubMed · Cited by 548
An activity phosphorylating tyrosine in polyoma T antigen immunoprecipitates
Eckhart, W., Hutchinson, M. A., & Hunter, T. R. (1979) · Cell · doi:10.1016/0092-8674(79)90205-8 · Cited by 539
Mutational Activation of the K-rasOncogene
Rodenhuis, S., van de Wetering, M. L., Mooi, W. J., Evers, S. G., van Zandwijk, N., & Bos, J. L. (1987) · New England Journal of Medicine · doi:10.1056/nejm198710083171504 · Cited by 537
Epidermal growth factor stimulates vascular endothelial growth factor production by human malignant glioma cells: a model of glioblastoma multiforme pathophysiology.
Goldman, C. K., Kim, J., Wong, W., King, V. J., Brock, T. A., & Gillespie, G. Y. (1993) · Molecular Biology of the Cell · doi:10.1091/mbc.4.1.121 · Cited by 531
Inherited susceptibility to lung cancer may be associated with the T790M drug resistance mutation in EGFR
Bell, D. W., Gore, I., Okimoto, R. A., Godin-Heymann, N., Sordella, R., Mulloy, R., Sharma, S. V., Brannigan, B. W., Mohapatra, G., Settleman, J., et al. (2005) · Nature Genetics · doi:10.1038/ng1671 · Cited by 529
Multicenter Phase II and Translational Study of Cetuximab in Metastatic Colorectal Carcinoma Refractory to Irinotecan, Oxaliplatin, and Fluoropyrimidines
Lenz, H., Cutsem, E. V., Khambata‐Ford, S., Mayer, R. J., Gold, P. J., Stella, P. J., Mirtsching, B. C., Cohn, A. L., Pippas, A. W., Azarnia, N., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.06.7595 · Cited by 528
Acquired resistance to EGFR tyrosine kinase inhibitors in cancer cells is mediated by loss of IGF-binding proteins
Guix, M., Faber, A. C., Wang, S. E., Olivares, M. G., Song, Y., Qu, S., Rinehart, C., Seidel, B., Yee, D., Arteaga, C. L., et al. (2008) · Journal of Clinical Investigation · doi:10.1172/jci34588 · Cited by 525
Insulin-like growth factor receptor I mediates resistance to anti-epidermal growth factor receptor therapy in primary human glioblastoma cells through continued activation of phosphoinositide 3-kinase signaling.
Chakravarti, A., Loeffler, J. S., & Dyson, N. J. (2002) · PubMed · Cited by 509
Prospective phase II study of gefitinib for chemotherapy-naive patients with advanced non-small-cell lung cancer with epidermal growth factor receptor gene mutations
Inoue, A., Suzuki, T., Fukuhara, T., Maemondo, M., Kimura, Y., Morikawa, N., Watanabe, H., Saijo, Y., & Nukiwa, T. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.05.4692 · Cited by 509
The tyrosine kinase inhibitor ZD1839 ("Iressa") inhibits HER2-driven signaling and suppresses the growth of HER2-overexpressing tumor cells.
Moasser, M. M., Basso, A., Averbuch, S. D., & Rosen, N. X. (2001) · PubMed · Cited by 508
First-line gefitinib for patients with advanced non-small-cell lung cancer harboring epidermal growth factor receptor mutations without indication for chemotherapy
Inoue, A., Kobayashi, K., Usui, K., Maemondo, M., Okinaga, S., Mikami, I., Ando, M., Yamazaki, K., Saijo, Y., Gemma, A., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.18.7658 · Cited by 505
ErbB-3 mediates phosphoinositide 3-kinase activity in gefitinib-sensitive non-small cell lung cancer cell lines
Engelman, J. A., Janne, P. A., Mermel, C. H., Pearlberg, J., Mukohara, T., Fleet, C., Cichowski, K. M., Johnson, B. E., & Cantley, L. C. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0409773102 · Cited by 500
Survival of Cancer Cells Is Maintained by EGFR Independent of Its Kinase Activity
Weihua, Z., Tsan, R. Z., Huang, W., Wu, Q., Chiu, C., Fidler, I. J., & Hung, M. (2008) · Cancer Cell · doi:10.1016/j.ccr.2008.03.015 · Cited by 495
Phase II Multicenter Study of the Antiepidermal Growth Factor Receptor Monoclonal Antibody Cetuximab in Combination With Platinum-Based Chemotherapy in Patients With Platinum-Refractory Metastatic and/or Recurrent Squamous Cell Carcinoma of the Head and Neck
Baselga, J. M., Trigo, J. M., Bourhis, J., Tortochaux, J., Cortés-Funes, H., Hitt, R., Gascón, P., Amellal, N., Harstrick, A., & Eckardt, A. M. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.07.119 · Cited by 491
Mutant Epidermal Growth Factor Receptor (EGFRvIII) Contributes to Head and Neck Cancer Growth and Resistance to EGFR Targeting
Sok, J. C., Coppelli, F. M., Thomas, S. M., Lango, M. N., Xi, S., Hunt, J. L., Freilino, M. L., Graner, M. W., Wikstrand, C. J., Bigner, D. D., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-0913 · Cited by 488
Phase I Study of Anti–Epidermal Growth Factor Receptor Antibody Cetuximab in Combination With Radiation Therapy in Patients With Advanced Head and Neck Cancer
Robert, F., Ezekiel, M. P., Spencer, S. A., Meredith, R. F., Bonner, J. A., Khazaeli, M. B., Saleh, M. N., Carey, D. E., LoBuglio, A. F., Wheeler, R. H., et al. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.13.3234 · Cited by 474
Expression of epidermal growth factor receptors in human brain tumors.
Libermann, T. A., Razon, N., Bartal, A. D., Yarden, Y., Schlessinger, J., & Soreq, H. (1984) · PubMed · Cited by 473
Point mutation at the ATP binding site of EGF receptor abolishes protein-tyrosine kinase activity and alters cellular routing
Honegger, A. (1987) · Cell · doi:10.1016/0092-8674(87)90147-4 · Cited by 469
Development of ABX-EGF, a fully human anti-EGF receptor monoclonal antibody, for cancer therapy
Yang, X. (2001) · Critical Reviews in Oncology/Hematology · doi:10.1016/s1040-8428(00)00134-7 · Cited by 463
Biological effects in vitro of monoclonal antibodies to human epidermal growth factor receptors.
Sato, J. D., Kawamoto, T., Le, A. D., Mendelsohn, J. M., Polikoff, J., & SATO, G. H. (1983) · PubMed · Cited by 458
The ErbB-2/HER2 oncoprotein of human carcinomas may function solely as a shared coreceptor for multiple stroma-derived growth factors
Klapper, L. N., Glathe, S., Vaisman, N., Hynes, N. E., Andrews, G. C., Sela, M., & Yarden, Y. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.9.4995 · Cited by 455
Epidermal growth factor stimulates phosphorylation in membrane preparations in vitro
Carpenter, G. F., King, L. E., & Cohen, S. (1978) · Nature · doi:10.1038/276409a0 · Cited by 454
Loss of PTEN/MMAC1/TEP in EGF receptor-expressing tumor cells counteracts the antitumor action of EGFR tyrosine kinase inhibitors
Bianco, R., Shin, I., Ritter, C. A., Yakes, F. M., Basso, A., Rosen, N. X., Tsurutani, J., Dennis, P. A., Mills, G. B., & Arteaga, C. L. (2003) · Oncogene · doi:10.1038/sj.onc.1206388 · Cited by 449
Cetuximab and First-Line Taxane/Carboplatin Chemotherapy in Advanced Non–Small-Cell Lung Cancer: Results of the Randomized Multicenter Phase III Trial BMS099
Lynch, T. J., Patel, T., Dreisbach, L., McCleod, M., Heim, W. J., Hermann, R. C., Paschold, E., Iannotti, N. O., Dakhil, S., Gorton, S., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.21.9618 · Cited by 447
Characterization of the binding of 125-I-labeled epidermal growth factor to human fibroblasts
Carpenter, G., Lembach, K. J., Morrison, M., & Cohen, S. (1975) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)41417-8 · Cited by 435
Antibody-Dependent Cellular Cytotoxicity Mediated by Cetuximab against Lung Cancer Cell Lines
Kurai, J., Chikumi, H., Hashimoto, K., Yamaguchi, K., Yamasaki, A., Sako, T., Touge, H., Makino, H., Takata, M., Miyata, M., et al. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-1726 · Cited by 435
The stimulation of epidermal proliferation by a specific protein (EGF)
Cohen, S. (1965) · Developmental Biology · doi:10.1016/0012-1606(65)90005-9 · Cited by 430
Randomized Phase II Trial of Cetuximab, Bevacizumab, and Irinotecan Compared With Cetuximab and Bevacizumab Alone in Irinotecan-Refractory Colorectal Cancer: The BOND-2 Study
Saltz, L. B., Lenz, H., Kindler, H. L., Höchster, H. S., Wadler, S., Hoff, P. M., Kemeny, N. E., Hollywood, E. M., Gönen, M., Quinones, M., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.12.0949 · Cited by 427
Phase III, Double-Blind, Randomized Study Comparing Lapatinib Plus Paclitaxel With Placebo Plus Paclitaxel As First-Line Treatment for Metastatic Breast Cancer
Leo, A. D., Gómez, H., Aziz, Z., Zvirbule, Z., Bines, J., Arbushites, M. C., Guerrera, S., Koehler, M. T., Oliva, C., Stein, S. H., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.16.2578 · Cited by 417
Lack of PTEN expression in non-small cell lung cancer could be related to promoter methylation.
Soria, J., Lee, H., Lee, J. I., Luo, W., Issa, J. J., Kemp, B. L., Liu, D. D., Kurie, J. M., Mao, L., & Khuri, F. R. (2002) · PubMed · Cited by 406
Heregulin‐dependent regulation of HER2/neu oncogenic signaling by heterodimerization with HER3.
Wallasch, C., Weiss, F. U., Niederfellner, G., Jallal, B., Issing, W., & Ullrich, A. (1995) · The EMBO Journal · doi:10.1002/j.1460-2075.1995.tb00101.x · Cited by 406
Phase II Multicenter Study of the Epidermal Growth Factor Receptor Antibody Cetuximab and Cisplatin for Recurrent and Refractory Squamous Cell Carcinoma of the Head and Neck
Herbst, R. S., Arquette, M. A., Shin, D. M., Dicke, K. A., Vokes, E. E., Azarnia, N., Hong, W. K., & Kies, M. S. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.07.120 · Cited by 402
Dual-Agent Molecular Targeting of the Epidermal Growth Factor Receptor (EGFR)
Huang, S., Armstrong, E., Benavente, S., Chinnaiyan, P., & Harari, P. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-0562 · Cited by 397
Self-citation
Phase II Study of Efficacy and Safety of Bevacizumab in Combination With Chemotherapy or Erlotinib Compared With Chemotherapy Alone for Treatment of Recurrent or Refractory Non–Small-Cell Lung Cancer
Herbst, R. S., O’Neill, V., Fehrenbacher, L., Belani, C. P., Bonomi, P., Hart, L. L., Melnyk, O. O., Ramies, D. A., Lin, M., & Sandler, A. B. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.12.3026 · Cited by 394
Signal transduction and oncogenesis by ErbB/HER receptors
Marmor, M. D., Skaria, K. B., & Yarden, Y. (2004) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2003.06.002 · Cited by 389
KRAS status and efficacy in the first-line treatment of patients with metastatic colorectal cancer (mCRC) treated with FOLFIRI with or without cetuximab: The CRYSTAL experience
Cutsem, E. V., Láng, I., D’Haens, G., Moiseyenko, V. M., Załuski, J., Folprecht, G., Tejpar, S., Kisker, O., Stroh, C., & Rougier, P. R. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.26.15_suppl.2 · Cited by 372
Targeting ADAM-mediated ligand cleavage to inhibit HER3 and EGFR pathways in non-small cell lung cancer
Zhou, B.-B., Peyton, M., He, B., Liu, C., Girard, L., Caudler, E., Lo, Y. Y. C., Baribaud, F., Mikami, I., Reguart, N., et al. (2006) · Cancer Cell · doi:10.1016/j.ccr.2006.05.024 · Cited by 370
Amphiregulin and epiregulin mRNA expression in primary tumors predicts outcome in metastatic colorectal cancer treated with cetuximab.
Jacobs, B., De Roock, W., Piessevaux, H., Van Oirbeek, R., Biesmans, B., De Schutter, J., Fieuws, S., Vandesompele, J., Peeters, M., Van Laethem, J.-L., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.21.3744 · Cited by 368
Anti-epidermal growth factor receptor monoclonal antibodies in cancer therapy
Martinelli, E., Palma, R. D., Orditura, M., Vita, F. D., & Ciardiello, F. (2009) · Clinical & Experimental Immunology · doi:10.1111/j.1365-2249.2009.03992.x · Cited by 348
Antitumor Activity of ZD6474, a Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor, in Human Cancer Cells with Acquired Resistance to Antiepidermal Growth Factor Receptor Therapy
Ciardiello, F., Bianco, R., Caputo, R., Caputo, R., Damiano, V., Troiani, T., Melisi, D., De Vita, F., De Placido, S., Bianco, A. R., et al. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-1100-03 · Cited by 347
Epidermal Growth Factor Receptor Gene Copy Number and Clinical Outcome of Metastatic Colorectal Cancer Treated With Panitumumab
Bianchi, A. S., Moroni, M., Veronese, S. M., Carnaghi, C., Bajetta, E., Luppi, G., Sobrero, A. F., Barone, C. A., Cascinu, S., Colucci, G., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.11.5956 · Cited by 336
Eradication of established tumors by a fully human monoclonal antibody to the epidermal growth factor receptor without concomitant chemotherapy.
Yang, X., Jia, X., Corvalan, J. R. F., Wang, P., Davis, C., & Jakobovits, A. (1999) · PubMed · Cited by 328
Epidermal growth factor receptors in non-small cell lung cancer
Veale, D., Ashcroft, T., Marsh, C., Gibson, G., & Harris, A. L. (1987) · British Journal of Cancer · doi:10.1038/bjc.1987.104 · Cited by 326
Nuclear EGFR signalling network in cancers: linking EGFR pathway to cell cycle progression, nitric oxide pathway and patient survival
Lo, H., & Hung, M.-C. (2006) · British Journal of Cancer · doi:10.1038/sj.bjc.6602941 · Cited by 324
Tyrosine phosphorylation controls PCNA function through protein stability
Wang, S., Nakajima, Y., Yu, Y. L., Xia, W., Chen, C.-T., Yang, C. C., McIntush, E. W., Li, L., Hawke, D. H., Kobayashi, R., et al. (2006) · Nature Cell Biology · doi:10.1038/ncb1501 · Cited by 322
Nuclear EGFR contributes to acquired resistance to cetuximab
Li, C., Iida, M., Dunn, E., Ghia, A. J., & Wheeler, D. L. (2009) · Oncogene · doi:10.1038/onc.2009.234 · Cited by 315
Self-citation
Differential Effects of Gefitinib and Cetuximab on Non–small-cell Lung Cancers Bearing Epidermal Growth Factor Receptor Mutations
Mukohara, T., Engelman, J. A., Hanna, N. H., Yeap, B. Y., Kobayashi, S. S., Lindeman, N. I., Halmos, B., Pearlberg, J., Tsuchihashi, Z., Cantley, L. C., et al. (2005) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/dji238 · Cited by 314
Epithelial-to-Mesenchymal Transition and Integrin-Linked Kinase Mediate Sensitivity to Epidermal Growth Factor Receptor Inhibition in Human Hepatoma Cells
Fuchs, B. C., Fujii, T., Dorfman, J. D., Goodwin, J. M., Zhu, A. X., Lanuti, M. D., & Tanabe, K. K. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-2460 · Cited by 308
Novel Prognostic Value of Nuclear Epidermal Growth Factor Receptor in Breast Cancer
Lo, H., Xia, W., Wei, Y., Ali‐Seyed, M., Huang, S.-F. K., & Hung, M. (2005) · Cancer Research · doi:10.1158/0008-5472.338.65.1 · Cited by 287
Resistance to gefitinib in PTEN-null HER-overexpressing tumor cells can be overcome through restoration of PTEN function or pharmacologic modulation of constitutive phosphatidylinositol 3'-kinase/Akt pathway signaling.
She, Q., Solit, D. B., Basso, A., & Moasser, M. M. (2003) · PubMed · Cited by 287
Inhibition of radiation-induced EGFR nuclear import by C225 (Cetuximab) suppresses DNA-PK activity
Dittmann, K., Mayer, C., & Rodemann, H. P. (2005) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2005.06.022 · Cited by 287
Epidermal growth factor ligand-independent, unregulated, cell-transforming potential of a naturally occurring human mutant EGFRvIII gene.
Batra, S. K., Castelino‐Prabhu, S., Wikstrand, C. J., Zhu, X., Humphrey, P. A., Friedman, H. S., & Bigner, D. D. (1995) · PubMed · Cited by 281
Epidermal‐Growth‐Factor‐Dependent Activation of the Src‐Family Kinases
Osherov, N., & Levitzki, A. (1994) · European Journal of Biochemistry · doi:10.1111/j.1432-1033.1994.1047b.x · Cited by 279
Antibody‐dependent cellular cytotoxicity of cetuximab against tumor cells with wild‐type or mutant epidermal growth factor receptor
Kimura, H., Sakai, K., Arao, T., Shimoyama, T., Tamura, T., & Nishio, K. (2007) · Cancer Science · doi:10.1111/j.1349-7006.2007.00510.x · Cited by 278
Combined Epidermal Growth Factor Receptor Targeting with the Tyrosine Kinase Inhibitor Gefitinib (ZD1839) and the Monoclonal Antibody Cetuximab (IMC-C225)
Matar, P., Rojo, F., Cassia, R., Moreno‐Bueno, G., Cosimo, S. D., Tabernero, J. M., Guzmán, M., Rodríguez, S., Arribas, J., Palacios, J., et al. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-0870 · Cited by 277
A phase II trial of gefitinib as first-line therapy for advanced non-small cell lung cancer with epidermal growth factor receptor mutations
Asahina, H., Yamazaki, K., Kinoshita, I., Sukoh, N., Harada, M., Yokouchi, H., Ishida, T., Ogura, S., Kojima, T., Okamoto, Y., et al. (2006) · British Journal of Cancer · doi:10.1038/sj.bjc.6603393 · Cited by 276
Quantitative Determination of Nuclear and Cytoplasmic Epidermal Growth Factor Receptor Expression in Oropharyngeal Squamous Cell Cancer by Using Automated Quantitative Analysis
Psyrri, A. K., Yu, Z., Weinberger, P., Sasaki, C. T., Haffty, B. G., Camp, R. L., Rimm, D. L., & Burtness, B. A. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-0420 · Cited by 276
Cooperative inhibitory effect of ZD1839 (Iressa) in combination with trastuzumab (Herceptin) on human breast cancer cell growth
Normanno, N., Campiglio, M., Luca, A. D., Somenzi, G., Maiello, M. R., Ciardiello, F., Gianni, L., Salomon, D. S., & Ménard, S. (2002) · Annals of Oncology · doi:10.1093/annonc/mdf020 · Cited by 272
Characterization of a Novel Tripartite Nuclear Localization Sequence in the EGFR Family
Hsu, S.-C., & Hung, M. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m610014200 · Cited by 272
Randomized phase II study of cetuximab plus cisplatin/vinorelbine compared with cisplatin/vinorelbine alone as first-line therapy in EGFR-expressing advanced non-small-cell lung cancer
Rosell, R., Robinet, G., Szczęsna, A., Ramlau, R., Constenla, M., Mennecier, B., Pfeifer, W., O'Byrne, K. J., Welte, T., Kolb, R., et al. (2007) · Annals of Oncology · doi:10.1093/annonc/mdm474 · Cited by 258
Signaling via ErbB2 and ErbB3 Associates with Resistance and Epidermal Growth Factor Receptor (EGFR) Amplification with Sensitivity to EGFR Inhibitor Gefitinib in Head and Neck Squamous Cell Carcinoma Cells
Erjala, K., Sundvall, M., Junttila, T. T., Zhang, N., Savisalo, M., Mali, P., Kulmala, J. A. J., Pulkkinen, J. O., Grenman, R. A., & Elenius, K. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-2404 · Cited by 257
Cetuximab: An epidermal growth factor receptor monoclonal antibody for the treatment of colorectal cancer
Wong, S. (2005) · Clinical Therapeutics · doi:10.1016/j.clinthera.2005.06.003 · Cited by 255
ras gene mutations in non-small cell lung cancers are associated with shortened survival irrespective of treatment intent.
Mitsudomi, T., Steinberg, S. M., Oie, H. K., Mulshine, J. L., Phelps, R. M., Viallet, J., Pass, H. I., Minna, J. D., & Gazdar, A. F. (1991) · PubMed · Cited by 248
EGFR signaling pathway in breast cancers: from traditional signal transduction to direct nuclear translocalization
Lo, H., Hsu, S.-C., & Hung, M. (2005) · Breast Cancer Research and Treatment · doi:10.1007/s10549-005-9011-0 · Cited by 240
KRAS status and efficacy of first-line treatment of patients with metastatic colorectal cancer (mCRC) with FOLFOX with or without cetuximab: The OPUS experience
Bokemeyer, C., Bondarenko, I., Hartmann, J. T., de Braud, F., Volovat, C. D., Nippgen, J., Stroh, C., Celik, I., & Koralewski, P. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.26.15_suppl.4000 · Cited by 240
Nuclear‐cytoplasmic transport of EGFR involves receptor endocytosis, importin β1 and CRM1
Lo, H., Ali‐Seyed, M., Wu, Y., Bartholomeusz, G. A., Hsu, S., & Hung, M. (2006) · Journal of Cellular Biochemistry · doi:10.1002/jcb.20876 · Cited by 240
A randomised phase III study on capecitabine, oxaliplatin and bevacizumab with or without cetuximab in first-line advanced colorectal cancer, the CAIRO2 study of the Dutch Colorectal Cancer Group (DCCG). An interim analysis of toxicity
Tol, J. A. M. G., Koopman, M., Rodenburg, C. J., Cats, A., Creemers, G. J., Schrama, J. G., Erdkamp, F., Vos, A. H., Mol, L., Antonini, N. F., et al. (2008) · Annals of Oncology · doi:10.1093/annonc/mdm607 · Cited by 211
Multicenter Phase I/II Study of Cetuximab With Paclitaxel and Carboplatin in Untreated Patients With Stage IV Non–Small-Cell Lung Cancer
Thienelt, C. D., Bunn, P. A., Hanna, N. H., Rosenberg, A., Needle, M. N., Long, M. E., Gustafson, D. L., & Kelly, K. L. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.03.1997 · Cited by 203
Nuclear epidermal growth factor receptor (EGFR) interacts with signal transducer and activator of transcription 5 (STAT5) in activating Aurora-A gene expression
Hung, L., Tseng, J. T.-C., Lee, Y., Xia, W., Wang, Y., Wu, M.-L., Chuang, Y.-H., Lai, C.-H., & Chang, W. (2008) · Nucleic Acids Research · doi:10.1093/nar/gkn417 · Cited by 203
Radiation-induced caveolin-1 associated EGFR internalization is linked with nuclear EGFR transport and activation of DNA-PK
Dittmann, K., Mayer, C., Kehlbach, R., & Rodemann, H. P. (2008) · Molecular Cancer · doi:10.1186/1476-4598-7-69 · Cited by 203
Nuclear Translocation of the Epidermal Growth Factor Receptor Family Membrane Tyrosine Kinase Receptors
Wang, S., & Hung, M. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-2813 · Cited by 196
Randomized Phase II Study of Gemcitabine Plus Cisplatin or Carboplatin, With or Without Cetuximab, As First-Line Therapy for Patients With Advanced or Metastatic Non–Small-Cell Lung Cancer
Butts, C. A., Bodkin, D., Middleman, E. L., Englund, C. W., Ellison, D. H., Alam, Y., Kreisman, H., Graze, P. R., Maher, J. F., Ross, H. J., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.13.0856 · Cited by 195
Cyclooxygenase-2 Is a Novel Transcriptional Target of the Nuclear EGFR-STAT3 and EGFRvIII-STAT3 Signaling Axes
Lo, H., Cao, X., Zhu, H., & Ali‐Osman, F. (2010) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-09-0391 · Cited by 195
A Mutant Epidermal Growth Factor Receptor with Defective Protein Tyrosine Kinase Is Unable To Stimulate Proto-Oncogene Expression and DNA Synthesis
Honegger, A., Szapary, D., Schmidt, A., Lyall, R. M., OBBERGHEN, E. V., Dull, T. J., Ullrich, A., & Schlessinger, J. (1987) · Molecular and Cellular Biology · doi:10.1128/mcb.7.12.4568 · Cited by 189
Co‐regulation of B‐Myb expression by E2F1 and EGF receptor
Hanada, N., Lo, H., Day, C., Pan, Y., Nakajima, Y., & Hung, M. (2005) · Molecular Carcinogenesis · doi:10.1002/mc.20147 · Cited by 188
Role of the Sec61 Translocon in EGF Receptor Trafficking to the Nucleus and Gene Expression
Liao, H., & Carpenter, G. F. (2007) · Molecular Biology of the Cell · doi:10.1091/mbc.e06-09-0802 · Cited by 187
Direct interaction of Cbl with pTyr 1045 of the EGF receptor (EGFR) is required to sort the EGFR to lysosomes for degradation
Grøvdal, L. M., Stang, E., Sorkin, A. D., & Madshus, I. H. (2004) · Experimental Cell Research · doi:10.1016/j.yexcr.2004.07.003 · Cited by 182
EGFRMutation Conferring Primary Resistance to Gefitinib in Non–Small-Cell Lung Cancer
Shih, J., Gow, C., & Yang, P. (2005) · New England Journal of Medicine · doi:10.1056/nejm200507143530217 · Cited by 177
Epidermal Growth Factor Receptor (EGFR) Ubiquitination as a Mechanism of Acquired Resistance Escaping Treatment by the Anti-EGFR Monoclonal Antibody Cetuximab
Lu, Y., Li, X., Liang, K., Luwor, R., Siddik, Z. H., Mills, G. B., Mendelsohn, J., & Fan, Z. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-0589 · Cited by 170
Specific inhibition of epidermal growth factor receptor tyrosine kinase by 4-anilinoquinazolines
Wakeling, A. E., Barker, A. J., Davies, D. H., Brown, D. S., Green, L. R., Cartlidge, S. A., & Woodburn, J. R. (1996) · Breast Cancer Research and Treatment · doi:10.1007/bf01803785 · Cited by 166
Prospective Validation for Prediction of Gefitinib Sensitivity by Epidermal Growth Factor Receptor Gene Mutation in Patients with Non-Small Cell Lung Cancer
Yoshida, K., Yatabe, Y., Park, J. Y., Shimizu, J., Horio, Y., Matsuo, K., Kosaka, T., Mitsudomi, T., & Hida, T. (2007) · Journal of Thoracic Oncology · doi:10.1016/s1556-0864(15)30013-7 · Cited by 165
Phosphotyrosine 1173 Mediates Binding of the Protein-tyrosine Phosphatase SHP-1 to the Epidermal Growth Factor Receptor and Attenuation of Receptor Signaling
Keilhack, H., Tenev, T., Nyakatura, E., Godovac‐Zimmermann, J., Nielsen, L., Seedorf, K., & Böhmer, F. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.38.24839 · Cited by 160
Resistance to Tyrosine Kinase Inhibition by Mutant Epidermal Growth Factor Receptor Variant III Contributes to the Neoplastic Phenotype of Glioblastoma Multiforme
Learn, C. A., Hartzell, T. L., Wikstrand, C. J., Archer, G. E., Rich, J. N., Friedman, A. H., Friedman, H. S., Bigner, D. D., & Sampson, J. H. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-03-0521 · Cited by 158
Epidermal Growth Factor Receptor cooperates with Src Family Kinases in acquired resistance to cetuximab
Wheeler, D. L., Iida, M., Kruser, T. J., Nechrebecki, M. M., Dunn, E. F., Armstrong, E. A., Huang, S., & Harari, P. M. (2009) · Cancer Biology & Therapy · doi:10.4161/cbt.8.8.7903 · Cited by 157
Self-citation
Epidermal Growth Factor Receptor Kinase Domain Mutations in Esophageal and Pancreatic Adenocarcinomas
Kwak, E. L., Jankowski, J. A., Thayer, S. P., Lauwers, G. Y., Brannigan, B. W., Harris, P. L., Okimoto, R. A., Haserlat, S. M., Driscoll, D. R., Ferry, D. R., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-0189 · Cited by 156
Nuclear expression of epidermal growth factor receptor is a novel prognostic value in patients with ovarian cancer
Xia, W., Wei, Y., Du, Y., Liu, J., Chang, B., Yu, Y., Huo, L., Miller, S. A., & Hung, M. (2008) · Molecular Carcinogenesis · doi:10.1002/mc.20504 · Cited by 151
Phase I/IIa Study of Cetuximab With Gemcitabine Plus Carboplatin in Patients With Chemotherapy-Naïve Advanced Non–Small-Cell Lung Cancer
Robert, F., Blumenschein, G., Herbst, R. S., Fossella, F. V., Tseng, J. E., Saleh, M. N., & Needle, M. N. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2004.00.1438 · Cited by 150
Vascular Endothelial Growth Factor Receptor-1 Contributes to Resistance to Anti–Epidermal Growth Factor Receptor Drugs in Human Cancer Cells
Bianco, R., Rosa, R., Damiano, V., Daniele, G., Gelardi, T., Garofalo, S., Tarallo, V., De Falco, S., Melisi, D., Benelli, R., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-4905 · Cited by 149
EGFR and KRAS mutations as criteria for treatment with tyrosine kinase inhibitors: retro- and prospective observations in non-small-cell lung cancer
van Zandwijk, N., Mathy, A., Boerrigter, L., Ruijter, H. J., Tielen, I. H. G., de Jong, D., Baas, P., Burgers, S. A., & Nederlof, P. M. (2006) · Annals of Oncology · doi:10.1093/annonc/mdl323 · Cited by 147
K‐ras mutations in human adenocarcinoma of the lung: Association with smoking and occupational exposure to asbestos
Husgafvel‐Pursiainen, K., Hackman, P., Ridanpää, M., Anttila, S. L., Karjalainen, A., Partanen, T. J., Taikina-aho, O., Heikkilä, L. J., & Vainio, H. (1993) · International Journal of Cancer · doi:10.1002/ijc.2910530213 · Cited by 145
Inactivation of thePTEN/MMAC1/TEP1 gene in human lung cancers
Kohno, T., Takahashi, M., Manda, R., & Yokota, J. (1998) · Genes Chromosomes and Cancer · doi:10.1002/(sici)1098-2264(199806)22:2 · Cited by 142
Nuclear targeting of Bax during apoptosis in human colorectal cancer cells
Mandal, M., Adam, L., Mendelsohn, J. M., & Kumar, R. (1998) · Oncogene · doi:10.1038/sj.onc.1202020 · Cited by 137
Localization of epidermal growth factor receptor in hepatocyte nuclei
Marti, U., Burwen, S. J., Wells, A. H., Barker, M. E., Huling, S. L., Feren, A. M., & Jones, A. L. (1991) · Hepatology · doi:10.1002/hep.1840130104 · Cited by 129
Randomized phase III study of capecitabine, oxaliplatin, and bevacizumab with or without cetuximab in advanced colorectal cancer (ACC), the CAIRO2 study of the Dutch Colorectal Cancer Group (DCCG)
Punt, C. J. A., Tol, J. A. M. G., Rodenburg, C. J., Cats, A., Creemers, G. J. M., Schrama, J. G., Erdkamp, F., Vos, A. H., Mol, L., & Antonini, N. F. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.26.15_suppl.lba4011 · Cited by 128
True
Liu, B., Fang, M., Schmidt, M., Lü, Y., Mendelsohn, J. M., & Fan, Z. (2000) · British Journal of Cancer · doi:10.1054/bjoc.2000.1201 · Cited by 125
Anti-Oncogenic Activity of Signalling-Defective Epidermal Growth Factor Receptor Mutants
Redemann, N. H., Holzmann, B., von Rüden, T., Wagner, E. F., Schlessinger, J., & Ullrich, A. (1992) · Molecular and Cellular Biology · doi:10.1128/mcb.12.2.491 · Cited by 125
Inhibition of proliferation and induction of apoptosis in breast cancer cells by the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor ZD1839 (‘Iressa’) is independent of EGFR expression level
Campiglio, M., Locatelli, A., Olgiati, C., Normanno, N., Somenzi, G., Viganò, L., Fumagalli, M., Ménard, S., & Gianni, L. (2003) · Journal of Cellular Physiology · doi:10.1002/jcp.10411 · Cited by 125
Adding cetuximab to capecitabine plus oxaliplatin (XELOX) in first-line treatment of metastatic colorectal cancer: a randomized phase II trial of the Swiss Group for Clinical Cancer Research SAKK
Borner, M., Koeberle, D., Von Moos, R., Saletti, P., Rauch, D., Hess, V., Trojan, A., Helbling, D., Pestalozzi, B., Caspar, C., et al. (2008) · Annals of Oncology · doi:10.1093/annonc/mdn058 · Cited by 124
Signaling-inactive epidermal growth factor receptor/ligand complexes in intact carcinoma cells by quinazoline tyrosine kinase inhibitors.
Lichtner, R. B., Menrad, A., Sommer, A., Klar, U., & Schneider, M. R. (2001) · PubMed · Cited by 121
Amplification and overexpression of the egf receptor gene in primary human glioblastomas
Libermann, T. A., Nusbaum, H. R., Razon, N., Kris, R., Lax, I., Soreq, H., Whittle, N., Waterfield, M. D., Ullrich, A., & Schlessinger, J. (1985) · Journal of Cell Science · doi:10.1242/jcs.1985.supplement_3.16 · Cited by 119
Insulin-like growth factor receptor 1 (IGFR-1) is significantly associated with longer survival in non-small-cell lung cancer patients treated with gefitinib
Cappuzzo, F., Toschi, L., Tallini, G., Ceresoli, G. L., Domenichini, I., Bartolini, S., Finocchiaro, G., Magrini, E., Metro, G., Cancellieri, A., et al. (2006) · Annals of Oncology · doi:10.1093/annonc/mdl077 · Cited by 97
Identification of residues in the nucleotide binding site of the epidermal growth factor receptor/kinase.
Russo, M. W., Lukas, T. J., Cohen, S., & Staros, J. V. (1985) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)89002-0 · Cited by 95
U.S. Food and Drug Administration Approval: Panitumumab for Epidermal Growth Factor Receptor–Expressing Metastatic Colorectal Carcinoma with Progression Following Fluoropyrimidine-, Oxaliplatin-, and Irinotecan-Containing Chemotherapy Regimens
Giusti, R. M., Shastri, K. A., Pilaro, A. M., Fuchs, C., Cordoba-Rodriguez, R., Koti, K. M., Rothmann, M. D., Men, A. Y., Zhao, H., Hughes, M., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-1354 · Cited by 93
Epidermal growth factor receptor gene amplification and expression in head and neck cancer cell lines
Weichselbaum, R. R., Dunphy, E. J., Beckett, M. A., Tybor, A. G., Moran, W. J., Goldman, M. E., Vokes, E. E., & Panje, W. R. (1989) · Head & Neck · doi:10.1002/hed.2880110510 · Cited by 89
Erlotinib Directly Inhibits HER2 Kinase Activation and Downstream Signaling Events in Intact Cells Lacking Epidermal Growth Factor Receptor Expression
Schaefer, G., Shao, L., Tótpál, K., & Akita, R. W. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-3493 · Cited by 87
More is less—combining targeted therapies in metastatic colorectal cancer
Punt, C. J. A., & Tol, J. (2009) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2009.168 · Cited by 76
Functional nuclear epidermal growth factor receptors in human choriocarcinoma JEG-3 cells and normal human placenta
Cao, H., Lei, Z. M., Bian, L., & Rao, C. V. (1995) · Endocrinology · doi:10.1210/endo.136.7.7540549 · Cited by 69
Erlotinib/gemcitabine for first-line treatment of locally advanced or metastatic adenocarcinoma of the pancreas.
Senderowicz, A. M., Johnson, J. R., Sridhara, R., Zimmerman, P., Justice, R. L., & Pazdur, R. (2007) · PubMed · Cited by 65
A phase II randomized selection trial evaluating concurrent chemotherapy plus cetuximab or chemotherapy followed by cetuximab in patients with advanced non-small cell lung cancer (NSCLC): Final report of SWOG 0342
Herbst, R. S., Chansky, K., Kelly, K. L., Atkins, J. N., Davies, A. M., Dakhil, S. R., Albain, K. S., Kim, E. S., Crowley, J. J., & Gandara, D. R. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.25.18_suppl.7545 · Cited by 53
A Novel Mechanism of Resistance to Epidermal Growth Factor Receptor Antagonism In vivo
Rajput, A., Koterba, A. P., Kreisberg, J. I., Foster, J. M., Willson, J. K. V., & Brattain, M. G. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-2773 · Cited by 50
Analysis of factors related to the occurrence of chronic disseminated candidiasis in patients with acute leukemia in a non-bone marrow transplant setting
Sallah, S., Wan, J. Y., Nguyen, N. P., Vos, P. W., & Sigounas, G. (2001) · Cancer · doi:10.1002/1097-0142(20010915)92:6 · Cited by 47
Mammary-Derived Growth Inhibitor Alters Traffic of EGFR and Induces a Novel Form of Cetuximab Resistance
Nevo, J., Mattila, E., Pellinen, T. S., Yamamoto, D. L., Sara, H., Iljin, K., Kallioniemi, O., Bono, P., Heikkilä, P., Joensuu, H., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-0773 · Cited by 37
Acquired Gefitinib-Resistant Mutation of EGFR in a Chemonaive Lung Adenocarcinoma Harboring Gefitinib-Sensitive Mutation L858R
Gow, C., Shih, J., Chang, Y., & Yu, C. (2005) · PLoS Medicine · doi:10.1371/journal.pmed.0020269 · Cited by 28
Antibodies to the ATP-binding site of the human epidermal growth factor (EGF) receptor as specific inhibitors of EGF-stimulated protein-tyrosine kinase activity
Gullick, W. J., Downward, J., Foulkes, J. G., & Waterfield, M. D. (1986) · European Journal of Biochemistry · doi:10.1111/j.1432-1033.1986.tb09744.x · Cited by 26
Untitled work
(2001) · PubMed

Sorted by citations

The biology and management of non-small cell lung cancer
Herbst, R. S., Morgensztern, D., & Boshoff, C. (2018) · Nature · doi:10.1038/nature25183 · Cited by 4,891
Epidermal Growth Factor Receptor Cell Proliferation Signaling Pathways
Wee, P., & Wang, Z. (2017) · Cancers · doi:10.3390/cancers9050052 · Cited by 2,027
MicroRNAs and other non-coding RNAs as targets for anticancer drug development
Ling, H. Y., Fabbri, M., & Călin, G. A. (2013) · Nature Reviews Drug Discovery · doi:10.1038/nrd4140 · Cited by 1,489
The quest to overcome resistance to EGFR-targeted therapies in cancer
Chong, C. R., & Janne, P. A. (2013) · Nature Medicine · doi:10.1038/nm.3388 · Cited by 1,076
Review on Epidermal Growth Factor Receptor (EGFR) Structure, Signaling Pathways, Interactions, and Recent Updates of EGFR Inhibitors
Sabbah, D. A., Hajjo, R., & Sweidan, K. (2020) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026620666200303123102 · Cited by 615

See all 687

Authors: Wheeler, D. L., Dunn, E. F., & Harari, P. M.
Affiliations: University of Wisconsin–Madison (US)
Corresponding author: Wheeler, Deric L.
ORCID: Wheeler, Deric L.
Dunn, Emily F.
Harari, Paul M.
Venue: Nature Reviews Clinical Oncology
Publisher: Springer Science and Business Media LLC
Published: 2010-06-15
Volume: 7
Issue: 9
Pages: 493-507
ISSN: 1759-4774 (ISSN-L)
1759-4782
DOI: 10.1038/nrclinonc.2010.97
PMC: PMC2929287
OpenAlex: W2053439872
Cited by: 683
References: 182
Citations by year: 2026: 21 · 2025: 20 · 2024: 35 · 2023: 29 · 2022: 31 · 2021: 29 · 2020: 44 · 2019: 25 · 2018: 36 · 2017: 50 · 2016: 46 · 2015: 61 · 2014: 66 · 2013: 68 · 2012: 64
FWCI: 6.61
Type: journal article
Language: en
Open access: green
www.ncbi.nlm.nih.gov
Licence: www.springer.com/tdm (tdm)
Locations: Nature Reviews Clinical Oncology (publishedVersion)
PubMed (publishedVersion)
PubMed Central (acceptedVersion)
Funders: National Institutes of Health (5t32ca009614-25)
U.S. Public Health Service (P30CAO14520)
National Cancer Institute (T-32 CA 0096-14, R01CA113448)
National Center for Research Resources (UL1RR025011)
Topics: Health Sciences › Medicine › Oncology › HER2/EGFR in Cancer Research
Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
Keywords: EGFR inhibitors, EGFR, acquired drug resistance, intrinsic resistance, tyrosine kinase inhibitors, resistance mechanisms, EGFR signaling, epithelial malignancies, lung cancer, head and neck cancer, colon cancer, pancreatic cancer, combination therapy
MeSH terms: Cetuximab, Erlotinib Hydrochloride, Gefitinib, Panitumumab, Antibodies, Monoclonal, Antineoplastic Agents, Humans, Neoplasms, Proto-Oncogene Proteins, Quinazolines, Proto-Oncogene Proteins p21(ras), Treatment Outcome, Disease Progression, ras Proteins, Drug Resistance, Neoplasm, Protein Kinase Inhibitors, Antibodies, Monoclonal, Humanized, ErbB Receptors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Understanding resistance to EGFR inhibitors—impact on future treatment strategies

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks